Study Identifies Potential Biomarker for Cabazitaxel Response in CRPC

Published on: 

The study published in Clinical Cancer Research elucidated an in vitro mechanism that could explain why cabazitaxel is more effective in some prostate cancer patients. The study also identified a biomarker that could provide precision medicine for a subset of patients.

Prostate cancer is the second leading cause of cancer for men in the United States. Only one class of chemotherapy called taxanes is effective against the disease. A study published online in

researchers have found that a newer member of the taxane family called cabazitaxel, an FDA approved drug, has properties that could make it more effective for some patients -- a hypothesis currently being tested in clinical trials. Researchers also found a genomic marker that could help physicians identify which patients might benefit most from cabazitaxel.

Clinical Cancer Research,


"It was surprising to find that cabazitaxel functions differently than docetaxel in killing cancer cells, even though they're both taxanes," says senior author Karen Knudsen, Ph.D., Interim Director of the Sidney Kimmel Cancer Center and a professor of cancer biology at the Sidney Kimmel Medical College at Thomas Jefferson University. "It shows that we may not be taking full advantage of this next generation taxane in the clinic."

For years, docetaxel has been the only effective chemotherapy for men whose cancer was no longer responding to hormone treatments. The next generation drug in the taxane family, cabazitaxel, was approved in 2010, but only for patients whose cancer no longer responded to hormone therapy or docetaxel treatment.

Read the complete article on ScienceDaily:

Discussions on current standards of care for prostate cancer can be found at: